Search results
Search for "γ-aminobutyric acid (GABA)" in Full Text gives 15 result(s) in Beilstein Journal of Organic Chemistry.
Synthesis and characterization of water-soluble C60–peptide conjugates
- Yue Ma,
- Lorenzo Persi and
- Yoko Yamakoshi
Beilstein J. Org. Chem. 2024, 20, 777–786, doi:10.3762/bjoc.20.71
- suitable for the coupling to peptides on resin, prepared by solid-phase peptide synthesis (SPPS) [35]. The detailed conditions for the amide-forming reaction were optimized using biscarboxylic acid-substituted C60 derivative 3 and a similar peptide with a primary amine derived from γ-aminobutyric acid
- (GABA) at the N-terminus of the Lys pentamer peptide on resin. Using the optimal reaction conditions, three types of hydrophilic peptide pentamers on resin, oligo-Lys (2a), oligo-Glu (2b), and oligo-Arg (2c), were subjected to the reaction with 3 for the synthesis of C60–peptide conjugates 5a–c (Figure
Graphical Abstract
Figure 1: a) Synthesis of C60–oligopeptide conjugates 5a–c and b) synthesis of compound 3. Fulleropyrrolidine...
Figure 2: Structure of C60–oligo-Lys (5a), C60–oligo-Glu (5b), and C60–oligo-Arg (5c) and images of dissolved...
Figure 3: DLS diagrams of C60–peptide conjugates 5a (1 mM, in Milli-Q® water), 5b (1 mM, in Milli-Q® water or...
Figure 4: UV–vis spectra of C60–peptide conjugates 5a and 5b (20 μM in Milli-Q® water for 5a and in pH 9.0 TR...
Figure 5: 1H NMR spectrum of C60–peptide conjugate 5a in D2O (above) and of the precursor monoadduct in CDCl3...
Figure 6: 13C NMR spectrum of C60–peptide conjugate 5a in D2O and of the precursor monoadduct in CDCl3 at 150...
Figure 7: a) X-band ESR spectra of the 4-oxo-TEMP adduct with 1O2 generated by C60–oligo-Lys (5a) and rose be...
Research progress on the pharmacological activity, biosynthetic pathways, and biosynthesis of crocins
- Zhongwei Hua,
- Nan Liu and
- Xiaohui Yan
Beilstein J. Org. Chem. 2024, 20, 741–752, doi:10.3762/bjoc.20.68
- and enhance the antiepileptic effect of diazepam. The mechanism of action involved γ-aminobutyric acid (GABA) [38][39][40]. The brain-derived neurotrophic factor (BDNF)–tropomyosin receptor kinase B (TrkB) pathway is closely associated with epilepsy. Crocin can increase the BDNF level in the cortex of
Graphical Abstract
Figure 1: Principal structure of crocin and crocetin derivatives, including common substituents of the crocet...
Figure 2: The pharmacological activity and mechanisms of action of crocins.
Figure 3: Crocin biosynthetic pathways in C. sativus and G. jasminoides. Enzyme abbreviations are as follows:...
Discovery of unguisin J, a new cyclic peptide from Aspergillus heteromorphus CBS 117.55, and phylogeny-based bioinformatic analysis of UngA NRPS domains
- Sharmila Neupane,
- Marcelo Rodrigues de Amorim and
- Elizabeth Skellam
Beilstein J. Org. Chem. 2024, 20, 321–330, doi:10.3762/bjoc.20.32
- de São Paulo, CP 780, CEP 13560-970, São Carlos, SP, Brazil 10.3762/bjoc.20.32 Abstract Several under-explored Aspergillus sp. produce intriguing heptapeptides containing a γ-aminobutyric acid (GABA) residue with as yet unknown biological functions. In this study, a new GABA-containing heptapeptide
- heptapeptides isolated predominantly from Aspergillus sp. [1][2][3][4][5][6][7][8]. Distinctive features of these cyclic peptides include the non-proteinogenic amino acid γ-aminobutyric acid (GABA) and the incorporation of up to five ᴅ-amino acids (Figure 1) [1][2][3][4][5][6][7][8]. The amino acids at
- γ-aminobutyric acid (GABA) (1 equiv). In addition to the COSY and HMBC correlations, the NOESY experiment showed important interactions between the NH signals corroborating with the peptide sequence defined to be Ala-1, Val-2, Leu-3, Phe-4, Ala-5, Trp-6, and GABA-7 (Figure 3). Analysis of the NMR
Graphical Abstract
Figure 1: Structures of unguisins.
Figure 2: Chemical structures of unguisin J (1) and unguisin B (2).
Figure 3: Key gHMBC and gCOSY correlations, and NOESY interactions of 1.
Figure 4: Clinker analysis of identified unguisin-encoding BGCs. UngE’ is a methyltransferase that methylates...
Scheme 1: Proposed biosynthesis of unguisins B and J in A. heteromorphus CBS 117.55.
Figure 5: Phylogenetic analysis of A domains extracted from UngA NRPS. The substrate of the A domain is indic...
Figure 6: Phylogenetic analysis of C domains extracted from UngA NRPS. The substrates condensed by each C dom...
Regioselective synthesis of methyl 5-(N-Boc-cycloaminyl)-1,2-oxazole-4-carboxylates as new amino acid-like building blocks
- Jolita Bruzgulienė,
- Greta Račkauskienė,
- Aurimas Bieliauskas,
- Vaida Milišiūnaitė,
- Miglė Dagilienė,
- Gita Matulevičiūtė,
- Vytas Martynaitis,
- Sonata Krikštolaitytė,
- Frank A. Sløk and
- Algirdas Šačkus
Beilstein J. Org. Chem. 2022, 18, 102–109, doi:10.3762/bjoc.18.11
- muscimol (I) and ibotenic acid (II) (Figure 1) have been isolated from several fungal species and are active on the γ-aminobutyric acid (GABA) and glutamate receptors of the central nervous system (CNS), respectively [8][9]. Various unnatural amino acids bearing a 1,2-oxazole moiety, such as
Graphical Abstract
Figure 1: Examples of amino-functionalized 1,2-oxazole derivatives I–VIII.
Scheme 1: Conversion of cyclic amino acids to 1,2-oxazole derivatives.
Scheme 2: Plausible mechanisms for the formation of 1,2-oxazoles 4a–h and VII from β-enamino ketoesters 3a–h ...
Figure 2: (a) 1H NMR (italics), 13C NMR (normal), and 15N NMR (bold) chemical shifts (ppm) of compound 3a in ...
Scheme 3: Synthesis of compound 15N-1,2-oxazole 5. The coupling constants of JHN and JCN from 15N2 are indica...
Figure 3: Stacked chromatogram view of pairs of enantiomers with area, %: (R)-4b, ee 100% (tR = 10.1 min) and...
Figure 4: (a) Structure of 4b with syn- and anti-conformers; (b) superimposed 1H NMR and 1D gradient NOE spec...
Scheme 4: Synthesis of 2-[4-(methoxycarbonyl)-1,2-oxazol-5-yl]cycloaminyl-1-ium trifluoroacetates 6a,b.
Figure 5: ORTEP diagram of the asymmetric unit consisting of two cations 6b(A) and 6b(B) and triflate anions.
Icilio Guareschi and his amazing “1897 reaction”
- Gian Cesare Tron,
- Alberto Minassi,
- Giovanni Sorba,
- Mara Fausone and
- Giovanni Appendino
Beilstein J. Org. Chem. 2021, 17, 1335–1351, doi:10.3762/bjoc.17.93
- -disubstituted glutarates, and the type-IV Guareschi synthesis is used in the preparation of the conformationally constrained γ-aminobutyric acid (GABA) analogue gabapentin (2) [3], a blockbuster drug for the management of neuropathic pain also used for a range of off-label indications that includes hot flashes
Graphical Abstract
Figure 1: Icilio Guareschi (1847–1918). (Source: Annali della Reale Accademia di Agricoltura di Torino 1919, ...
Scheme 1: Vitamin B6 (pyridoxine, 1), gabapentin (2), and thymol (3).
Figure 2: Baliatico (Nursing) by Francesco Scaramuzza (275 cm × 214 cm, Parma, Complesso Museale della Pilott...
Figure 3: Schiff’s fictitious report on the foundation of the Gazzetta Chimica Italiana (Image reproduced fro...
Scheme 2: Reaction of thymol (3) with chloroform under the basic conditions of the Guareschi–Lustgarten react...
Figure 4: The chemistry building of Turin University in a historical picture. Note, that one of the “mysterio...
Scheme 3: Triacetonamine (6) and the related compounds phorone (7), α-eucaine (8), and tropinone (9).
Scheme 4: Taxonomy of the Guareschi pyridone syntheses.
Scheme 5: The catalytic cycle of the “1897 reaction”.
Scheme 6: Resonance forms of the radical 10.
Figure 5: The wet chamber used by Guareschi to restore parchments (Gorrini, G. L'incendio della R. Biblioteca...
Figure 6: The Guareschi mask. (Servizio Chimico Militare. L'opera di Icilio Guareschi precursore della masche...
Figure 7: Guareschi’s bust at the Dipartimento di Scienza e Tecnologia del Farmaco of Turin University. Permi...
Synthesis of new tricyclic 5,6-dihydro-4H-benzo[b][1,2,4]triazolo[1,5-d][1,4]diazepine derivatives by [3+ + 2]-cycloaddition/rearrangement reactions
- Lin-bo Luan,
- Zi-jie Song,
- Zhi-ming Li and
- Quan-rui Wang
Beilstein J. Org. Chem. 2018, 14, 1826–1833, doi:10.3762/bjoc.14.155
- examples of such clinically drugs having enhanced effects on the neurotransmitter γ-aminobutyric acid (GABA) at the GABAA receptor and low toxicity (Figure 1) [15]. Although 1,4-benzodiazepines are widely prescribed medicines, side effects like drowsiness, drug resistance, addiction and withdrawal
Graphical Abstract
Figure 1: Examples of marketed pharmaceutical 1,2,4-triazolobenzodiazepines.
Scheme 1: Preparation of N-acylated 2,3-dihydro-4(1H)-quinolones 6.
Scheme 2: Synthesis of α-acetoxyazo compounds 8a–g. Reaction conditions: for synthesis of 8a: 7a (10.42 mmol)...
Scheme 3: Synthesis of tricyclic benzo[b][1,2,4]triazolo[1,5-d][1,4]diazepinium salts 10. Reaction conditions...
Scheme 4: Synthesis of N(1)-unsubstituted benzo[b][1,2,4]triazolo[1,5-d][1,4]diazepines 13. Reaction conditio...
Scheme 5: Mechanistic rationale for the [3+ + 2]-cycloaddition/rearrangement reaction.
Figure 2: Crystal structure of salt 10k. The displacement ellipsoids are drawn at the 30% probability level.
Figure 3: Crystal structure of the free base 13e. The displacement ellipsoids are drawn at the 30% probabilit...
Novel amide-functionalized chloramphenicol base bifunctional organocatalysts for enantioselective alcoholysis of meso-cyclic anhydrides
- Lingjun Xu,
- Shuwen Han,
- Linjie Yan,
- Haifeng Wang,
- Haihui Peng and
- Fener Chen
Beilstein J. Org. Chem. 2018, 14, 309–317, doi:10.3762/bjoc.14.19
- pharmaceuticals, such as γ-aminobutyric acid (GABA) and γ-amino-β-hydroxybutyric acid (GABOB) analogues (baclofen HCl and pregabalin) [51][52][53][54], HMG-CoA reductase inhibitors (“statins”) [55][56][57], etc. The generality and scope of this methodology was further demonstrated in the alcoholysis of 8a with
Graphical Abstract
Figure 1: Chloramphenicol-base-derived bifunctional organocatalysts.
Figure 2: Design of new chloramphenicol base amide organocatalysts.
Scheme 1: Synthesis of bifunctional amide catalysts 7a–q.
Scheme 2: Asymmetric synthesis of (S)-GABOB (13).
Expression, purification and structural analysis of functional GABA transporter 1 using the baculovirus expression system
- Jing Hu,
- Chris Weise,
- Christoph Böttcher,
- Hua Fan and
- Jian Yin
Beilstein J. Org. Chem. 2017, 13, 874–882, doi:10.3762/bjoc.13.88
- Avenue1800, Wuxi 214122, China 10.3762/bjoc.13.88 Abstract The γ-aminobutyric acid (GABA) transporter 1 (GAT1) belongs to a family of Na+ and Cl−-coupled transport proteins and possesses 12 putative transmembrane domains. To perform structural analyses of the GAT1 protein, the GAT1/green fluorescent protein
- isolated in its monomeric form. Keywords: baculovirus expression system; chromatography; γ-aminobutyric acid (GABA); GABA transporter 1 (GAT1); Introduction γ-Aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the central nervous system (CNS) of vertebrate species. GABAergic
Graphical Abstract
Figure 1: Expression of GFP-tagged GAT1 in infected insect cells. (A) Flow cytometry analysis of GAT1/GFP in ...
Figure 2: Protein fingerprinting. (A) Coomassie Blue staining of the GAT1/GFP protein from infected Sf9 cells...
Figure 3: Isolation of the GAT1/GFP fusion protein from Sf9 cells by mAb-GFP-conjugated affinity column chrom...
Figure 4: Purification of the GAT1/GFP fusion protein from Sf9 cells by SE-FPLC. (A) Elution profile of GAT1/...
Figure 5: Characterization of the GAT1/GFP fusion protein after SE-FPLC. (A) Elution profile of GAT1/GFP prot...
Contribution of microreactor technology and flow chemistry to the development of green and sustainable synthesis
- Flavio Fanelli,
- Giovanna Parisi,
- Leonardo Degennaro and
- Renzo Luisi
Beilstein J. Org. Chem. 2017, 13, 520–542, doi:10.3762/bjoc.13.51
- isolation of intermediates, separation of the catalyst or other work-up procedures can be considered sustainable [91]. The syntheses of (S)-rolipram and a γ-aminobutyric acid (GABA) derivative were accomplished. Readily available starting materials and columns containing chiral heterogeneous catalysts to
Graphical Abstract
Figure 1: Microreactor technologies and flow chemistry for a sustainable chemistry.
Scheme 1: A flow microreactor system for the generation and trapping of highly unstable carbamoyllithium spec...
Scheme 2: Flow synthesis of functionalized α-ketoamides.
Scheme 3: Reactions of benzyllithiums.
Scheme 4: Trapping of benzyllithiums bearing carbonyl groups enabled by a flow microreactor. (Adapted with pe...
Scheme 5: External trapping of chloromethyllithium in a flow microreactor system.
Scheme 6: Scope for the direct tert-butoxycarbonylation using a flow microreactor system.
Scheme 7: Control of anionic Fries rearrangement reactions by using submillisecond residence time. (Adapted w...
Figure 2: Chip microreactor (CMR) fabricated with six layers of polyimide films. (Reproduced with permission ...
Scheme 8: Flow microreactor system for lithiation, borylation, Suzuki–Miyaura coupling and selected examples ...
Scheme 9: Experimental setup for the flow synthesis of 2-fluorobi(hetero)aryls by directed lithiation, zincat...
Scheme 10: Experimental setup for the coupling of fluoro-substituted pyridines. (Adapted with permission from [53]...
Scheme 11: Continuous flow process setup for the preparation of 11 (Reproduced with permission from [54], copyrigh...
Scheme 12: Continuous-flow photocatalytic oxidation of thiols to disulfides.
Scheme 13: Trifluoromethylation by continuous-flow photoredox catalysis.
Scheme 14: Flow photochemical synthesis of 6(5H)-phenanthridiones from 2-chlorobenzamides.
Scheme 15: Synthesis of biaryls 14a–g under photochemical flow conditions.
Scheme 16: Flow oxidation of hydrazones to diazo compounds.
Scheme 17: Synthetic use of flow-generated diazo compounds.
Scheme 18: Ley’s flow approach for the generation of diazo compounds.
Scheme 19: Iterative strategy for the sequential coupling of diazo compounds.
Scheme 20: Integrated synthesis of Bakuchiol precursor via flow-generated diazo compounds.
Scheme 21: Kappe’s continuous-flow reduction of olefines with diimide.
Scheme 22: Multi-injection setup for the reduction of artemisinic acid.
Scheme 23: Flow reactor system for multistep synthesis of (S)-rolipram. Pumps are labelled a, b, c, d and e; L...
Figure 3: Reconfigurable modules and flowcharts for API synthesis. (Reproduced with permission from [85], copyrig...
Figure 4: Reconfigurable system for continuous production and formulation of APIs. (Reproduced with permissio...
New GABA amides activating GABAA-receptors
- Peter Raster,
- Andreas Späth,
- Svetlana Bultakova,
- Pau Gorostiza,
- Burkhard König and
- Piotr Bregestovski
Beilstein J. Org. Chem. 2013, 9, 406–410, doi:10.3762/bjoc.9.42
- ; GABA; GABA-amides; GABA-superagonist; patch-clamp recording; Introduction γ-Aminobutyric acid (GABA) is the major inhibitory amino acid transmitter of the central nervous system (CNS) of vertebrates (Figure 1). It plays an important role in a variety of physiological functions, including motion
Graphical Abstract
Figure 1: The neurotransmitter GABA.
Scheme 1: Synthesis of GABA-amide hydrochlorides 4a–c and 6a–f. (i) THF, reflux; (ii) MeOH, HCl (5%); (iii) T...
Figure 2: Effect of 7b on GABAA-receptor activation. (A) Superimposed traces of whole-cell currents induced b...
Figure 3: Absence of GABAA-receptor activation on application of 4c. Top traces: Examples of whole-cell curre...
Figure 4: Variation of EC50 values with the number n of methylene units separating the amide and the ammonium...
Figure 5: Effect of 7d on GABAA-receptor activation. (A,B) Superimposed traces of whole-cell currents induced...
Enantioselective total synthesis of (R)-(−)-complanine
- Krystal A. D. Kamanos and
- Jonathan M. Withey
Beilstein J. Org. Chem. 2012, 8, 1695–1699, doi:10.3762/bjoc.8.192
- with a γ-aminobutyric acid (GABA) derivative. Complanine is structurally related to the obscuraminols, isolated from another marine source, the ascidian Pseudodistoma obscurum [2]. Unlike complanine, however, these substances are simple amino alcohols that do not possess any other chemical
Graphical Abstract
Figure 1: Structure of (R)-(−)-complanine.
Scheme 1: Retrosynthetic analysis of (R)-(−)-complanine.
Scheme 2: Reagents and conditions: (a) Cs2CO3, CuI, TBAI, DMF, rt, 24 h, 91%; (b) H2 (1 atm), Lindlar catalys...
Scheme 3: Direct approach to amino alcohol 4.
Scheme 4: Reagents and conditions: (a) 2-Nitrosotoluene, L-proline (10 mol %), CHCl3, 0 °C, 3 h; (b) NaBH4, E...
An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
- Marcus Baumann,
- Ian R. Baxendale,
- Steven V. Ley and
- Nikzad Nikbin
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
- , and is part of the imidazopyridine class of pharmaceuticals. It is an agonist for the target receptor of γ-aminobutyric acid (GABA), an inhibitory neurotransmitter. Zolpidem binds to GABA receptors at the same site as typical benzodiazepines. This drug is preferred to benzodiazepines for long term use
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
The C–F bond as a conformational tool in organic and biological chemistry
- Luke Hunter
Beilstein J. Org. Chem. 2010, 6, No. 38, doi:10.3762/bjoc.6.38
- and 28 adopt the illustrated conformations about the C8–C9 bond in methanol solution. Biological probes γ-Aminobutyric acid (GABA, 29, Figure 6) is an important neurotransmitter molecule. It is quite a flexible molecule, with 3 rotatable C–C bonds. GABA (29) binds to several different proteins
Graphical Abstract
Figure 1: Conformational effects associated with C–F bonds.
Figure 2: HIV protease inhibitor Indinavir (17) and fluorinated analogues 18 and 19. In analogue 18 the gauche...
Figure 3: Cholesteryl ester transfer protein inhibitors 20 and 21. In the fluorinated analogue 21, nO→σ*CF hy...
Figure 4: HIV reverse transcriptase inhibitor 22 and acid-stable fluorinated analogues 23–25. The F–C–C–O gau...
Figure 5: Dihydroquinidine (26) and fluorinated analogues 27 and 28. Newman projections along the C9–C8 bonds...
Figure 6: The neurotransmitter GABA (29) and fluorinated analogues (R)-30 and (S)-30. Newman projections of (R...
Figure 7: The insect pheromone 31 and fluorinated analogues (S)-32 and (R)-32. The proposed bioactive conform...
Figure 8: Capsaicin (33) and fluorinated analogues (R)-34 and (S)-34.
Figure 9: Asymmetric epoxidation reaction catalysed by pyrrolidine 35. Inset: the geometry of the activated i...
Figure 10: The asymmetric transannular aldol reaction catalysed by trans-4-fluoroproline (41), and its applica...
Figure 11: The asymmetric Stetter reaction catalysed by chiral NHC catalysts 49–52. The ring conformations of ...
Figure 12: A multi-vicinal fluoroalkane.
Figure 13: X-ray crystal structures of diastereoisomeric multi-vicinal fluoroalkanes 55 and 56. The different ...
Figure 14: Examples of fluorinated liquid crystal molecules. Arrows indicate the orientation of the molecular ...
Figure 15: Di-, tri- and tetra-fluoro liquid crystal molecules 60–62.
Figure 16: Collagen mimics of general formula (Pro-Yaa-Gly)10 where Yaa is either 4(R)-hydroxyproline (63) or ...
Figure 17: Enkephalin-related peptide 64 and the fluorinated analogue 65. The electron-withdrawing trifluorome...
Figure 18: The C–F bond influences the conformation of β-peptides. β-Heptapeptide 66 adopts a helical conforma...
Figure 19: The conformations of pseudopeptides 69 and 70 are influenced by the α-fluoroamide effect and the fl...
Molecular recognition of organic ammonium ions in solution using synthetic receptors
- Andreas Späth and
- Burkhard König
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
- similar binaphthyl crown recognition systems containing phenylboronic acid 40a and 2,4-dinitrophenylurea 40b as lariat parts [178] (Figure 23). Host 40a had 30% extraction efficiency for γ-aminobutyric acid (GABA) in solid–liquid extraction in DMSO, but showed only much lower selectivities for α-amino
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...
(−)-Complanine, an inflammatory substance of marine fireworm: a synthetic study
- Kazuhiko Nakamura,
- Yu Tachikawa and
- Daisuke Uemura
Beilstein J. Org. Chem. 2009, 5, No. 12, doi:10.3762/bjoc.5.12
- ; thus, the biological properties of complanine can be understood as controlling this cascade [2]. From a structural perspective, complanine possesses amphipathic properties due to its characteristic unsaturated carbon chain and a γ-aminobutyric acid (GABA)-derived trimethylammonium substructure. Natural
- identical to the degradation product of natural complanine (NMR, MS and Rf value of TLC). The activated ester (hydroxysuccinimide ester) of 4-(trimethylammonio)butanoate was synthesized from the commercially available γ-aminobutyric acid (GABA) in two steps (1. MeI, NaHCO3, MeOH, rt, 24 h; 2. HOSu; DCC
Graphical Abstract
Figure 1: Structure of (R)-(−)-complanine.
Figure 2: Marine fireworm Eurythoe complanata (body length 10 cm).
Scheme 1: Total synthesis of complanine. Keys: a) 1. BH3·SMe2 (71%); 2. cat. TsOH, Et2CO (59%); 3. TsCl, pyri...
